-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Balapiravir
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/690270-29-2.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 690270-29-2 |
| Description | Balapiravir is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase. It is the tri-isobutyrate ester prodrug of R1479 under clinical development to improve exposure of R1479 upon oral administration. It was discontinued for safety reasons in 28-36% of patients and the percentage of patients with serious adverse events was dose related. |
Product Information
| Synonyms | R1626; R-1626; R 1626; RO4588161; RO-4588161; RO 4588161; Balapiravir. |
| Molecular Weight | 494.5 |
| Molecular Formula | C21H30N6O8 |
| Canonical SMILES | CC(C)C(=O)OCC1(C(C(C(O1)N2C=CC(=NC2=O)N)OC(=O)C(C)C)OC(=O)C(C)C)N=[N+]=[N-] |
| InChI | InChI=1S/C21H30N6O8/c1-10(2)17(28)32-9-21(25-26-23)15(34-19(30)12(5)6)14(33-18(29)11(3)4)16(35-21)27-8-7-13(22)24-20(27)31/h7-8,10-12,14-16H,9H2,1-6H3,(H2,22,24,31)/t14-,15+,16-,21-/m1/s1 |
| InChIKey | VKXWOLCNTHXCLF-DXEZIKHYSA-N |
| Purity | >98% |
| Solubility | In Vitro: DMSO : ≥ 100 mg/mL(202.22 mM) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.06 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (5.06 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.5 mg/mL (5.06 mM); Clear solution |
| Appearance | Off-white to light yellow (Solid) |
| Storage | Powder: -20°C 3 years 4°C 2 years In solvent: -80°C 6 months -20°C 1 months |
| Complexity | 971 |
| Exact Mass | 494.21251194 |
| In Vitro | After oral dosing of the CD-1 mice with 28.1 mg/kg of balapiravir (Ro 4588161; R1626), R1479 reaches a Cmax and a minimum concentration in plasma (Cmin) of 24.38 μM and 6.34 μM, respectively, at 2 h and 24 h postdosing, |
| PSA | 198.79000 |
| Target | HCV; DNA/RNA Synthesis |
| XLogP3-AA | 2.5 |